Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2019

Open Access 01-12-2019 | Magnetic Resonance Imaging | ASO Author Reflections

ASO Author Reflections: Similar Short- and Long-Term Outcomes in Variable Use and Timing of Restaging MRI and Surgery After Preoperative Chemoradiotherapy for Rectal Cancer

Authors: Robin Detering, MD, Pieter J. Tanis, MD, PhD

Published in: Annals of Surgical Oncology | Special Issue 3/2019

Login to get access

Excerpt

Preoperative chemoradiotherapy (CRT) has become standard of care in the treatment of patients with locally advanced rectal cancer. CRT results in downsizing facilitating complete resection and reduces the local recurrence rate, and 15–20% of patients achieve pathological complete response (pCR), which is associated with favorable oncological outcomes.1 However, one of the unresolved issues regarding preoperative CRT is the optimal time interval to total mesorectal excision (TME) surgery and the role of magnetic resonance imaging (MRI) restaging in clinical decision-making. …
Literature
1.
Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathologic complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99:918–28.CrossRef
2.
Lefevre JH, Mineur L, Simon T, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016;34:3773–3780.CrossRef
3.
4.
Beets GL, Figueiredo NL, Habr-Gama A, et al. A new paradigm for rectal cancer: organ preservation: introducing the international watch and wait database (IWWD). Eur J Surg Oncol. 2015;41(12):1562–4.CrossRef
5.
Beets-Tan RGH, Lambregts DMJ, Maas M, et al. Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol. 2018;28:1465.CrossRef
Metadata
Title
ASO Author Reflections: Similar Short- and Long-Term Outcomes in Variable Use and Timing of Restaging MRI and Surgery After Preoperative Chemoradiotherapy for Rectal Cancer
Authors
Robin Detering, MD
Pieter J. Tanis, MD, PhD
Publication date
01-12-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07286-y

Other articles of this Special Issue 3/2019

Annals of Surgical Oncology 3/2019 Go to the issue

ASO Author Reflections

ASO Author Reflections: Genetic and Immunohistochemical Studies Investigating the Histogenesis of Neuroendocrine and Carcinomatous Components of Combined Neuroendocrine Carcinoma

ASO Author Reflections

ASO Author Reflections: Effect of Noncompliance in Lymph Node Dissection on the Long-Term Survival of Gastric Cancer Patients After Radical Gastrectomy

ASO Author Reflections

ASO Author Reflections: ARL4C and Peritoneal Dissemination in Gastric Cancer

ASO Author Reflections

ASO Author Reflections: Proposal of a New Preoperative Score to Predict Resectability in Pseudomyxoma Peritonei

ASO Author Reflections

ASO Author Reflections: Splenic Hilar Nodal Dissection for Proximal Advanced Gastric Cancer

Correction

Correction to: The Immunoscore is a Superior Prognostic Tool in Stages II and III Colorectal Cancer and is Significantly Correlated with Programmed Death-Ligand 1 (PD-L1) Expression on Tumor-Infiltrating Mononuclear Cells